Mar.26.2021
R & D
Bristol Myers Squibb Announces RELATIVITY-047, a Trial Evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo (nivolumab) in Patients with Previously Untreated Metastatic or Unresectable Melanoma Meets Primary Endpoint of Progression-Free Survival
This material is intended to notify the press release issued on March 25 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
Please click https://www.bms.com/media/press-releases.html for the original press release.